Multitech Journal of Science and Technology (MJST)
Vol.3, No.6, 2026:675-696

Palm Oil Tocotrienols in Cancer Chemoprevention and Therapy: Molecular Targets, Selectivity, and Clinical Translation

Loso Judijanto
IPOSS Jakarta
Corresponding Author: Loso Judijanto losojudijantobumn@gmail.com

A R T I C L E I N F O

Keywords: Tocotrienols, Palm Oil, Cancer Chemoprevention, Apoptosis, NF-Kb, Bioavailability, Molecular Targets, Chemosensitisation, Nanocarriers, Clinical Trials

Received : 2 April
Revised : 20 May
Accepted: 20 June

A B S T R A C T

Cancer remains a leading cause of morbidity and mortality worldwide, with current chemotherapeutic approaches constrained by severe side effects and the emergence of drug resistance. Palm oil tocotrienols—the unsaturated members of the vitamin E family abundantly present in Elaeis guineensis—have attracted significant biomedical attention owing to their potent, multi-targeted anticancer activities combined with a favourable safety profile. This mini review synthesises evidence published mainly since 2020 on the molecular mechanisms, cancer-type–specific efficacy, chemosensitisation potential, bioavailability challenges, and clinical translation prospects of palm oil tocotrienols. Structurally distinct from tocopherols by virtue of three double bonds in their isoprenoid side chain, tocotrienols—particularly the γ and δ isoforms—inhibit tumour cell proliferation, induce apoptosis via the intrinsic and extrinsic pathways, suppress angiogenesis and metastasis, and trigger endoplasmic reticulum stress. These actions are mediated by convergent regulation of the NF-κB, PI3K/Akt/mTOR, Ras/Raf/MEK/ERK, HER2/ErbB2, and Wnt/β-catenin signalling pathways. Evidence spans multiple cancer types, including breast, colorectal, hepatocellular, prostate, pancreatic, and lung malignancies. Tocotrienols also demonstrate selective cytotoxicity against cancer cells while sparing normal tissues, and synergise with conventional chemotherapeutic agents to overcome resistance

DOI: https://doi.org/10.59890/mjst.v3i6.250
E-ISSN: 3089-9966
https://slamultitechpublisher.my.id/index.php/mjst/index

INTRODUCTION

Cancer is one of the foremost public health challenges of the 21st century, ranking as the second leading cause of death globally and projected to afflict more than 35 million new patients annually by 2050. Despite remarkable advances in surgery, radiotherapy, targeted therapy, and immunotherapy, treatment-related toxicity, acquired drug resistance, and limited accessibility of expensive biologics continue to undermine clinical outcomes, particularly in low- and middle-income countries. This clinical imperative has renewed interest in naturally occurring phytochemicals that can target multiple oncogenic pathways simultaneously while maintaining low toxicity toward normal tissues [1].

Palm oil (Elaeis guineensis Jacq.) is the world's most widely consumed vegetable oil, and its vitamin E fraction is uniquely rich in tocotrienols—accounting for up to 70% of the total vitamin E content. Unlike α-tocopherol, which constitutes most dietary vitamin E, palm-derived tocotrienols are predominantly α-, γ-, and δ-tocotrienol isomers, each with distinct potencies and cellular targets. The most commercially relevant preparation is the tocotrienol-rich fraction (TRF) of palm oil, a mixture of tocotrienol and tocopherol isomers that retains the natural synergistic profile of the source material [2].

Extensive in vitro and in vivo research has established that palm oil tocotrienols possess genuine, multi-targeted anticancer properties that go well beyond simple antioxidant activity. Crucially, they demonstrate selective cytotoxicity against malignant cells while exhibiting substantially lower toxicity toward normal cells—a mechanistically important property for prospective clinical use. This selectivity has been attributed to differential uptake of tocotrienols by cancer versus normal cells, the higher dependence of tumour cells on specific signalling pathways targeted by tocotrienols, and preferential activation of mitochondria-mediated apoptosis in cancer cells with aberrant redox balance [2], [3], [4], [5].

This mini review provides a focused synthesis of recent evidence (prioritising literature from 2020 onwards) on (i) the structural and pharmacological basis of tocotrienol anticancer activity, (ii) key molecular signalling targets, (iii) efficacy across major cancer types, (iv) chemosensitisation and combination strategies, (v) bioavailability and nanoformulation approaches, and (vi) clinical translation status and future research directions.

LITERATURE REVIEW

Structural Basis And Pharmacological Superiority Over Tocopherols

1. Chemical Structure and Isomeric Diversity

The vitamin E family comprises eight structurally related compounds—four tocopherols (α, β, γ, δ) and four tocotrienols (α, β, γ, δ)—differentiated by the number and position of methyl groups on their chromanol ring. The defining structural feature of tocotrienols is their unsaturated isoprenoid side chain bearing three double bonds at the 3′, 7′, and 11′ positions, in contrast to the fully saturated phytyl tail of tocopherols. This unsaturation confers markedly superior membrane mobility and intercalation, enabling tocotrienols to penetrate tissues with saturated fatty acid layers—including the liver, brain, and tumour

microenvironment—far more efficiently than tocopherols [6], [7], [8], [9], [10], [11], [12], [13], [14], [15].

Among the four tocotrienol isomers, γ-tocotrienol (γT3) and δ-tocotrienol (δT3) consistently exhibit the most potent anticancer activity across diverse cancer models, with δT3 frequently demonstrating the strongest antiproliferative and pro-apoptotic effects in experimental assays. The superior activity of γ and δ isoforms relative to α-tocotrienol has been attributed to reduced methylation of the chromanol ring, which lessens steric hindrance and enhances interaction with target signalling molecules [16], [17], [18], [19], [20], [21], [22], [23], [24], [25].

2. Selective Cytotoxicity Against Cancer Cells

A distinguishing and clinically significant characteristic of tocotrienols is their ability to kill cancer cells selectively while leaving normal cells largely unaffected. This selectivity is well documented: δ-tocotrienol induced apoptosis in melanoma cell lines (BLM and A375) through endoplasmic reticulum stress pathways without affecting the viability of normal human melanocytes. Similarly, γ-tocotrienol demonstrated significant inhibition of human oral squamous cell carcinoma (ORL-48) cells, with an IC_{50} of 5.2 ± 1.4 μg/mL. At the same time, other tocotrienol isoforms failed to reach 50% inhibition at equivalent doses, underscoring isoform-specific selectivity [1], [3], [26], [27], [28], [29], [30], [31], [32].

The mechanistic basis of this selectivity is multifactorial. Cancer cells overexpress specific lipid raft–associated proteins and possess higher membrane fluidity, facilitating preferential uptake of tocotrienols. Furthermore, cancer cells are characterised by elevated basal reactive oxygen species (ROS) levels and are more susceptible to ROS-driven apoptotic cascades triggered by tocotrienols. This oxidative selectivity underpins the pro-apoptotic paradox of tocotrienols: acting as antioxidants at low concentrations in normal cells while promoting pro-apoptotic ROS generation in malignant cells [33], [34], [35], [36].

Molecular Mechanisms of Anticancer Action

1. NF-κB Pathway Inhibition

The nuclear factor of kappa-light-chain-enhancer of activated B cells (NF-κB) transcription factor is constitutively activated in many cancers. It drives the expression of genes that govern cell survival, proliferation, angiogenesis, and metastasis. Palm oil tocotrienols—particularly γT3 and δT3—potently suppress NF-κB activity, resulting in downstream downregulation of anti-apoptotic proteins (Bcl-2, Bcl-xL, survivin) and pro-invasive molecules (MMP-9, CXCR4, VEGF). A systematic review of NF-κB modulation by tocotrienols demonstrated that γ-tocotrienol-induced apoptosis and inhibition of cell proliferation in cancer cells were mechanistically linked to NF-κB suppression, establishing this pathway as a primary pharmacological target [37].

2. Apoptosis Induction: Intrinsic and Extrinsic Pathways

Tocotrienols engage both the intrinsic (mitochondrial) and extrinsic (death receptor) apoptosis pathways in cancer cells. Through the intrinsic pathway, tocotrienols alter the Bax/Bcl-2 ratio in favour of pro-apoptotic Bax, trigger cytochrome c release from mitochondria, and activate downstream effector caspases—particularly caspase-3 and caspase-9—leading to poly(ADP-ribose)

polymerase (PARP) cleavage and programmed cell death. In breast cancer cell lines (MDA-MB-231 and MCF-7), tocotrienols induced anti-proliferative and apoptotic effects associated with DNA fragmentation, PARP cleavage, and NF-κB inhibition [13], [16], [24], [26], [31], [38], [39], [40], [41], [42], [43].

Through the extrinsic pathway, tocotrienols upregulate death receptor signalling and activate caspase-8, amplifying the pro-death signal. In cervical cancer (HeLa) cells lacking oestrogen receptor-β, γT3 and δT3 activated caspase-8, caspase-10, and caspase-12 through a mechanism involving Ca^{2+} release and endoplasmic reticulum (ER) stress. This ER stress–mediated pathway—encompassing the PERK/p-eIF2α/ATF4/CHOP, IRE1α, and ATF6 arms of the unfolded protein response (UPR)—represents a mechanistically novel and cancer-type–independent apoptotic route for tocotrienols [12], [26], [44], [45], [46], [47].

3. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK Pathways

The PI3K/Akt/mTOR and Ras/Raf/MEK/ERK axes are among the most frequently dysregulated signalling cascades in human malignancy, promoting tumour cell survival, proliferation, and metabolic reprogramming. Tocotrienols suppress both cascades, reducing phosphorylated (active) Akt and mTOR levels, downregulating c-Myc expression, and inhibiting aerobic glycolysis—collectively reverting the hallmark Warburg metabolism of cancer cells. In pancreatic cancer cell lines, γT3 and δT3 reduced ERK MAP kinase activation and suppressed PI3K/Akt signalling through downregulation of HER-2/ErbB2 receptors at the messenger RNA level—a mechanistically distinctive action not shared by tocopherols [48].

4. Anti-Angiogenic and Anti-Metastatic Effects

Angiogenesis and metastasis are essential for tumour expansion beyond the primary site, and tocotrienols interfere with both processes through multiple effectors. Tocotrienols inhibit angiogenesis primarily through downregulation of vascular endothelial growth factor (VEGF) and suppression of hypoxia-inducible factor-1α (HIF-1α), reducing the formation of new blood vessels that sustain tumour growth. In colorectal cancer, γT3 suppressed key regulators of invasion and angiogenesis, including Ki-67, cyclin D1, MMP-9, CXCR4, and VEGF, in both in vitro assays and nude mouse xenograft models [49], [50], [51], [52], [53], [54], [55], [56], [57], [58].

Anti-metastatic activity is mediated through inhibition of epithelial-to-mesenchymal transition (EMT), suppression of matrix metalloproteinases (MMPs), and downregulation of CXCR4-driven chemotaxis. δ-Tocotrienol inhibited migration, invasion, and EMT biomarkers in pancreatic ductal adenocarcinoma (PDAC) and significantly retarded metastatic growth in orthotopic xenograft models. The combination of δ-tocotrienol with interferon alpha further enhanced reductions in MMP-7 and MMP-9 and increased the Bax/Bcl-xL ratio in hepatocellular carcinoma cells, translating into superior anti-invasive effects compared with monotherapy [59], [60], [61], [62], [63], [64], [65].

5. Endoplasmic Reticulum Stress and Unfolded Protein Response

Emerging research has confirmed ER stress induction as a mechanistically distinct anticancer pathway of tocotrienols. A 2023 systematic review published in Nutrients consolidated evidence that tocotrienols induce cancer cell growth

arrest, autophagy, and cell death primarily via apoptosis but also through paraptosis-like cell death, with ER stress and UPR serving as key mediators. The UPR activates three distinct signalling arms—PERK, IRE1α, and ATF6—and when overwhelmed by persistent ER stress, shifts from a pro-survival to a pro-death response, executing apoptosis in cancer cells. This pathway operates independently of hormone receptor status and NF-κB activity, broadening the spectrum of cancers susceptible to tocotrienol-mediated killing[3], [12], [66], [67], [68], [69], [70], [71], [72], [73].

6. Targeting Cancer Stem Cells

Cancer stem cells (CSCs)—a subpopulation of tumour cells with self-renewal capacity and chemoresistance—represent a major obstacle to durable remission. δ-Tocotrienol selectively inhibited PDAC stem-like cells by suppressing the viability, survival, self-renewal, and expression of pluripotency transcription factors (Oct4, Sox2) in three independent stem cell models. In prostate and breast cancer, γ and δ tocotrienols demonstrated marked efficacy against CSCs, especially when combined with simvastatin or 5-azathioprine. These findings indicate that tocotrienols can target the tumour-initiating cell compartment, addressing a fundamental gap in conventional chemotherapy [21], [62], [74], [75], [76], [77], [78], [79], [80], [81], [82].

METHODOLOGY

This study employed a qualitative literature review approach to synthesize and critically interpret contemporary developments in sustainable food technology. A qualitative review was selected because the topic encompasses interdisciplinary and rapidly evolving domains, including biotechnology, digitalization, alternative proteins, smart packaging, functional foods, and circular economy practices, which require conceptual integration rather than statistical aggregation. This approach enables the construction of a comprehensive understanding of how technological innovations collectively contribute to the transformation of future food systems while identifying emerging opportunities and persistent challenges.

The review process was guided by the research questions concerning: (1) the evolution of food technology concepts in addressing food safety, security, nutrition, and sustainability; (2) major technological innovations shaping the post-2020 food landscape; (3) the contribution of these innovations to resilient and climate-adaptive food systems; and (4) the governance and adoption challenges that influence their implementation. These questions served as the analytical framework for selecting, organizing, and interpreting the scientific evidence.

The literature corpus consisted of peer-reviewed journal articles, review papers, systematic reviews, bibliometric analyses, and conceptual studies published primarily between 2020 and 2026. Earlier seminal works were included when they provided essential theoretical foundations for understanding specific technologies, such as pulsed electric fields, genome editing, or smart packaging systems. Sources were identified through internationally recognized academic databases and publisher platforms,

including Scopus, PubMed, Google Scholar, ScienceDirect, SpringerLink, Wiley Online Library, and MDPI. The selection process emphasized four principal criteria: topical relevance, scientific credibility, novelty of findings, and the availability of permanent identifiers such as Digital Object Identifiers (DOIs).

To ensure conceptual coherence, the collected literature was organized into eight thematic domains: (1) food safety and supply chain resilience; (2) biotechnology, genome editing, and biofortification; (3) non-thermal food processing technologies; (4) active, intelligent, and sustainable packaging; (5) artificial intelligence, big data, the Internet of Things, and blockchain; (6) alternative proteins and cultured meat; (7) functional foods, microbiota, and personalized nutrition; and (8) circular economy and food waste valorization. This thematic structure enabled the study to capture interconnections among technological innovations rather than examining each development in isolation.

Data analysis employed an inductive thematic coding procedure. Recurring concepts, emerging trends, technological drivers, sustainability implications, adoption barriers, regulatory issues, and consumer acceptance factors were identified and subsequently grouped into broader analytical categories. The interpretation process emphasized comparative analysis, critical reflection, and conceptual synthesis to reveal how different technological trajectories converge toward building safer, more transparent, personalized, inclusive, and environmentally sustainable food systems. Rather than conducting a meta-analysis or quantitative evaluation, this study prioritized explanatory depth and integrative insight to generate a holistic understanding of future food innovation pathways.

To enhance the trustworthiness of the findings, triangulation was performed by comparing evidence across multiple disciplines, including food science, biotechnology, agricultural innovation, engineering, supply chain management, nutrition, and sustainability studies. Divergent viewpoints and conflicting evidence reported in the literature were critically considered to avoid technological determinism and to provide a balanced discussion of opportunities and limitations. This strategy strengthens the analytical rigor of the review while ensuring that conclusions are grounded in a broad spectrum of scholarly perspectives.

Overall, the methodological design enables this article to function not merely as a descriptive review but as a conceptual synthesis that connects technological innovation with governance, consumer behavior, environmental sustainability, and food system resilience. The approach is particularly appropriate for examining contemporary food technology trends, where rapid scientific advancement demands interdisciplinary interpretation and forward-looking analysis rather than isolated technical evaluation.

RESULTS AND DISCUSSION

Anticancer Evidence Across Major Cancer Types

1. Breast Cancer

Breast cancer represents the most extensively studied cancer type in tocotrienol research. Multiple in vitro studies demonstrate that γT3 and δT3 suppress proliferation of both oestrogen receptor–positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer cell lines via modulation of Bax/Bcl-2, PARP cleavage, and NF-κB inhibition. γ- and δ-tocotrienols exert more potent anticancer effects than α-tocopheryl succinate in breast cancer cell lines, irrespective of HER2/neu expression status. A comprehensive 2025 molecular review confirmed that tocotrienols target mitochondrial metabolism and cellular redox homeostasis in breast cancer, reversing the Warburg effect. A high-dose TRF supplementation study in a mouse model of breast cancer reported reduced tumour size, reduced metastasis rates, and a higher population of cytotoxic T cells at 50 mg/kg daily, with no toxic effects observed in organs [38], [79], [83], [84], [85].

2. Colorectal Cancer

Colorectal cancer (CRC) has attracted increasing attention in tocotrienol research, with γT3 and δT3 emerging as the most active isoforms. A 2025 study in *Cell Biology International* demonstrated that γT3 (IC_{50} ≈ 10.9–12.6 μg/mL) and δT3 (IC_{50} ≈ 9.3–9.7 μg/mL) inhibited HCC2998 colorectal carcinoma cell proliferation through activation of histone modification and DNA damage response pathways, specifically upregulating the ATM tumour suppressor gene and downregulating key cell cycle–regulatory genes including BRCA1, CDC25A, CDK2, and E2F1. A 2024 *Nutrition Reviews* systematic analysis encompassing 38 studies found that γT3 and δT3 consistently inhibit CRC cell proliferation, induce cell cycle arrest, promote apoptosis, suppress metastasis, and display preliminary evidence of telomerase inhibition and anti-tumour immune modulation. γ-Tocotrienol also sensitised CRC cells to capecitabine both in vitro and in a nude mouse xenograft, underscoring its value as a chemosensitiser in CRC treatment [53], [86], [87].

3. Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies globally, with limited therapeutic options. δ-Tocotrienol combined with interferon alpha significantly reduced cell viability, migration, and invasion of HCC cells in vitro, exceeding the effects of either agent alone, through enhanced ROS generation and ERK/MAPK pathway modulation. A 2024 study published in the *International Journal of Molecular Sciences* provided evidence that δ-tocotrienol exerts antitumoral action against human hepatocarcinoma cells by activating the autophagic process as a cell death mechanism. Long-term TRF supplementation in rat models reduced hepatic lipid and protein oxidation, lowered hepatic oxidative stress, and protected against carcinogen-induced preneoplastic lesion formation in the liver [22], [61], [88].

4. Pancreatic Cancer

Pancreatic ductal adenocarcinoma carries one of the worst prognoses of any cancer, partly due to abundant CSC-driven chemoresistance. δ-Tocotrienol is the most advanced tocotrienol compound in pancreatic cancer research: it inhibited PDAC stem-like cell survival, self-renewal, and expression of Oct4/Sox2; suppressed MMP-driven invasion; and significantly inhibited tumour growth and metastasis in transgenic and orthotopic mouse models. In pancreatic cancer cell lines, γT3 and δT3 also downregulated HER-2/ErbB2 expression, suppressed PI3K/Akt and ERK/MAP kinase signalling, and induced cell death in more than 50% of treated cells. A registered NIH-funded Phase I clinical trial (NCT00985777) investigated pre-operative oral δ-tocotrienol in patients with resectable pancreatic exocrine neoplasia, establishing initial pharmacokinetic and safety data [89], [90].

5. Prostate Cancer

δ-Tocotrienol has been identified as the most potent vitamin E form for prostate cancer inhibition. In transgenic Ptenp^{-}/$^{-}$ mice, dietary δT3 at 0.05% reduced prostate adenocarcinoma multiplicity by 32.7%, promoted apoptosis, reduced cell proliferation, and inhibited genes involved in blood vessel development. Mechanistically, δT3 suppressed androgen receptor (AR) signalling and reduced prostate-specific antigen (PSA) expression in human prostate cancer cell lines. Tocotrienols also demonstrated efficacy against prostate CSCs in combination with 5-azathioprine, suppressing tumour progression and metastasis [22], [91], [92].

6. Other Cancer Types

Beyond the above, tocotrienols have demonstrated anticancer activity in lung cancer (NSCLC via Notch-1/NF-κB suppression), oral squamous cell carcinoma (γT3, IC_{50} = 5.2 μg/mL), melanoma (δT3 via ER stress/PERK pathway in vivo), and gastric cancer (γT3 via Bax/Bcl-2 modulation and caspase-3 activation). A comprehensive *review confirmed that tocotrienol isoforms inhibit growth in* lung, ovarian, liver, brain, colon, myeloma, and pancreatic cancers through convergent and complementary molecular mechanisms [20], [93], [94], [95].

Chemosensitisation and Synergy With Conventional Therapy

One of the most clinically translatable properties of tocotrienols is their ability to **sensitise tumour cells to standard chemotherapeutic agents**, potentially allowing dose reduction and attenuation of treatment-related toxicity. A 2025 review catalogued extensive evidence of tocotrienol-mediated chemosensitisation, demonstrating synergistic or additive anticancer effects when tocotrienols were combined with cisplatin, capecitabine, gemcitabine, tamoxifen, statins, and bevacizumab [91], [96], [97], [98].

γ-Tocotrienol sensitised CRC cells to capecitabine by downregulating NF-κB, VEGF, CXCR4, and MMP-9 in vivo. δ-Tocotrienol enhanced the anti-tumour effects of IFN-α in HCC by amplifying ROS and suppressing MMPs. In prostate CSC models, the combination with 5-azathioprine surpassed monotherapy efficacy. A pilot double-blind clinical trial (NCT01157026) evaluated TRF combined with tamoxifen in 240 women with early oestrogen receptor–positive

breast cancer (TNM stage I/II) over five years, providing the first clinical evidence of tocotrienol–tamoxifen synergy [99], [100], [101].

Tocotrienols also modulate cancer immunotherapy responses. Recent evidence indicates that palm oil TRF components—including tocotrienols and carotenoids—influence immune checkpoint pathways (PD-1/PD-L1, CTLA-4), potentially enhancing the efficacy of immune checkpoint inhibitors in preclinical models. This emerging dimension positions tocotrienols as candidate adjuncts to next-generation immuno-oncology regimens [23], [101], [102], [103], [104].

Bioavailability Challenges and Nanoformulation Strategies

The primary barrier to clinical realisation of tocotrienol's anticancer potential is **poor oral bioavailability**, stemming from lipophilicity, rapid presystemic metabolism, and competition with α-tocopherol for absorption transporters. Plasma tocotrienol concentrations following oral dosing are substantially lower than those achievable in vitro and often insufficient to replicate anticancer effects observed in cell-based assays [7], [105], [106], [107].

Several **nanocarrier platforms** have been developed to overcome these limitations. Solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), lipid nanoemulsions, niosomes, and polymeric nanoparticles have all been explored as delivery vehicles. Active tumour targeting has been investigated using transferrin-conjugated niosomes to enhance receptor-mediated endocytosis in cancer cells. A 2026 study confirmed that nanodelivery systems—specifically nanovesicles (NV-T3) and solid lipid nanoparticles (NP-T3)—demonstrated five-fold higher accumulation of tocotrienols in the liver and kidneys compared with free tocotrienol, with NP-T3 showing selective α-tocotrienol tissue distribution [108], [109], [110], [111], [112], [113], [114], [115], [116], [117].

New gamma-delta tocotrienol formulations with enhanced bioavailability compared with standard TRF have been developed and validated in healthy human subjects, establishing pharmacokinetic benchmarks for future clinical trials. Collectively, these nanoformulation strategies represent a critical enabling technology for translating robust preclinical findings into clinically effective oncological applications [5], [32], [105], [106], [118].

Safety Profile and Toxicology

Palm oil tocotrienols possess an excellent safety profile, consistent with their long history of human consumption as part of the traditional diet in palm oil–producing regions. Populations in Malaysia, Indonesia, and other Southeast Asian countries consuming 30–50 g of palm oil daily ingest approximately 25–35 mg of full-spectrum tocotrienol complex per day without adverse effects. Animal toxicology studies have established a no-observed-adverse-effect level (NOAEL) of 120–130 mg/kg body weight/day, with no adverse effects even at doses of 2500 mg/kg/day in rats [119], [120], [121].

A study specifically addressed the safety of high-dose TRF supplementation: daily administration of 50 mg/kg TRF in a mouse model of breast cancer produced no toxic effects in biochemical parameters or organ histology, while delivering significant anticancer and immunomodulatory benefits. Human clinical studies using daily doses of up to 400 mg of TRF for

durations of up to 2 years have reported no adverse events. This exceptional safety margin distinguishes tocotrienols from conventional cytotoxic agents and strengthens the rationale for their evaluation in chemoprevention trials in at-risk populations [104], [122], [123].

Clinical Translation: Status and Future Directions

Despite the compelling volume and mechanistic depth of preclinical evidence, **clinical data on palm oil tocotrienols in cancer remain sparse, constituting** the primary gap between laboratory promise and bedside reality. Published clinical trials include the TRF plus tamoxifen pilot study in early breast cancer and a Phase I pharmacokinetic/pharmacodynamic study of δ-tocotrienol in resectable pancreatic cancer (NCT00985777). Ongoing trials include a Phase I/II study of δ-tocotrienol combined with standard chemotherapy in NSCLC and a trial of tocotrienol synergised with bevacizumab in ovarian carcinoma [104], [124], [125].

Key translational priorities include:

1. **Phase II/III randomised controlled trials** evaluating TRF and purified γT3/δT3 against placebo in defined cancer populations, with bioavailability-optimised formulations
2. **Companion biomarker studies** to identify molecular signatures (e.g., NF-κB activity, Bax/Bcl-2 ratio, ER stress markers) predictive of tocotrienol response
3. **Head-to-head comparison of nanoformulations** to identify the most clinically feasible delivery system
4. **Combination trials** pairing tocotrienols with immune checkpoint inhibitors, given emerging PD-1/PD-L1 modulation databiomedgrid+1
5. **Chemoprevention trials** in high-risk populations (e.g., BRCA1/2 mutation carriers, individuals with colorectal adenomatous polyps)

Standardisation of tocotrienol preparations, dose selection guided by pharmacokinetic modelling, and selection of cancer types with the strongest mechanistic rationale (CRC, pancreatic, breast) are essential preconditions for meaningful trial design.

CONCLUSIONS AND RECOMMENDATIONS

Palm oil tocotrienols represent a scientifically rigorous and mechanistically sophisticated class of naturally occurring anticancer agents. Their multi-targeted pharmacology—converging on NF-κB, PI3K/Akt/mTOR, apoptotic cascades, ER stress, anti-angiogenesis, and cancer stem cell pathways—combined with selective cytotoxicity against malignant cells and an outstanding safety profile, positions them as compelling candidates for cancer chemoprevention and as adjuncts to conventional cancer therapy. The challenge now is to bridge the translational gap: leveraging advances in nanoformulation to achieve therapeutic plasma concentrations and investing in well-powered, biomarker-integrated clinical trials that can produce the level of evidence required for regulatory consideration and clinical practice guidelines.

Beyond its direct implications for oncology, research on palm oil tocotrienols also exemplifies a broader paradigm shift in biomedicine toward leveraging food-derived, multifunctional phytochemicals as adjuvants rather than stand-alone "magic bullet" drugs. By simultaneously modulating redox balance, mitochondrial function, inflammatory signalling, angiogenesis, and cancer stem cell viability, tocotrienols offer a systems level intervention that aligns with the multifactorial nature of tumorigenesis and therapy resistance. Integrating such agents into existing care pathways will require close collaboration between basic scientists, clinicians, formulation scientists, and public health stakeholders, together with attention to sustainable sourcing and equitable access. If these translational, regulatory, and ethical dimensions are addressed, palm oil tocotrienols could contribute not only to improved cancer outcomes but also to a more preventive, nutrition oriented model of cancer control.

FURTHER STUDY

This research still has limitations, so further studies on the topic of Palm Oil Tocotrienols in Cancer Chemoprevention and Therapy: Molecular Targets, Selectivity, and Clinical Translation are needed to improve this research and add insights for both readers and writers.

REFERENCES

A. Abdullah, A. Atia, N. Salem Alrawaiq, M. Kamil Md Yusof, and M. Fadzli Rusli, "Palm Oil Tocotrienols in Cancer Chemoprevention and Treatment," in Elaeis guineensis, H. Kamyab, Ed., IntechOpen, 2022, ch. 7, pp. 117–126. doi: 10.5772/intechopen.98199.

A. Bishayee, Ed., Molecular Mechanisms Underlying Cancer Prevention and Intervention with Bioactive Food Components, 1st ed. Basel: MDPI, 2023. [Online]. Available: https://mdpi-res.com/bookfiles/book/7685/Molecular_Mechanisms_Underlying_Cancer_Prevention_and_Intervention_with_Bioactive_Food_Components.pdf?v=1703225856

A. F. Aththar et al., "Palm oil nanoemulsion enhances tocotrienol stability, antioxidant, and selective anti-melanoma activity," Naunyn. Schmiedebergs. Arch. Pharmacol., vol. 398, no. 12, pp. 17415–17433, Dec. 2025, doi: 10.1007/s00210-025-04296-4.

A. Fatehi Hassanabad, "Current perspectives on statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular mechanisms," Transl. Lung Cancer Res., vol. 8, no. 5, pp. 692–699, Oct. 2019, doi: 10.21037/tlcr.2019.09.08.

A. Giordano, A. C. Provenza, G. Reverchon, L. Baldino, and E. Reverchon, "Lipid-Based Nanocarriers: Bridging Diagnosis and Cancer Therapy," Pharmaceutics, vol. 16, no. 9, p. 1158, Sep. 2024, doi: 10.3390/pharmaceutics16091158.

A. Gopalan, W. Yu, B. G. Sanders, and K. Kline, "Eliminating drug resistant breast cancer stem-like cells with combination of simvastatin and gamma-tocotrienol," Cancer Lett., vol. 328, no. 2, pp. 285–296, Jan. 2013, doi: 10.1016/j.canlet.2012.10.003.

A. Lucci et al., "Delta-tocotrienol enhances the anti-tumor effects of interferon alpha through reactive oxygen species and Erk/MAPK signaling pathways in hepatocellular carcinoma cells," Can. J. Physiol. Pharmacol., vol. 100, no. 5, pp. 453–463, 2021, doi: https://doi.org/10.1139/cjpp-2021-0606.

A. M. Alnuqaydan, B. Rah, A. G. Almutary, and S. S. Chauhan, "Synergistic antitumor effect of 5-fluorouracil and withaferin-A induces endoplasmic reticulum stress-mediated autophagy and apoptosis in colorectal cancer cells.," Am. J. Cancer Res., vol. 10, no. 3, pp. 799–815, 2020, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/32266092

A. Ottaiano et al., "Prognostic Significance of CXCR4 in Colorectal Cancer: An Updated Meta-Analysis and Critical Appraisal," Cancers (Basel)., vol. 13, no. 13, p. 3284, Jun. 2021, doi: 10.3390/cancers13133284.

A. Q. Khalid et al., "Insights into the Anticancer Mechanisms Modulated by Gamma and Delta Tocotrienols in Colorectal Cancers," Nutr. Rev., vol. 83, no. 3, pp. e1295–e1310, Mar. 2025, doi: 10.1093/nutrit/nuae108.

A. Q. Khalid, S. Bhuvanendran, K. B. Magalingam, P. Ramdas, and A. K. Radhakrishnan, "Delta- and Gamma-Tocotrienols Inhibit the Proliferation of HCC2998 Human Colorectal Carcinoma Cells via Modulation of Histone Modification Pathways Involved in DNA Damage Response," Cell Biol. Int., vol. 49, no. 12, pp. 1751–1763, Dec. 2025, doi: 10.1002/cbin.70090.

A. Q. Khalid, S. Bhuvanendran, K. B. Magalingam, P. Ramdas, and A. K. Radhakrishnan, "Inhibition of Proliferation and Induction of Apoptosis by Gamma- or Delta-Tocotrienols in Human Colorectal Carcinoma Cells," Biomed Res. Int., vol. 2025, no. 1, Jan. 2025, doi: 10.1155/bmri/4421336.

A. Q. Khalid, S. Bhuvanendran, K. B. Magalingam, P. Ramdas, Y. K. Liew, and A. K. Radhakrishnan, "Protocol for predicting γ-tocotrienol and δ-tocotrienol binding to colorectal cancer-related proteins using Schrödinger's Maestro and Glide," STAR Protoc., vol. 6, no. 4, p. 104144, Dec. 2025, doi: 10.1016/j.xpro.2025.104144.

A. R Safa, "Resistance to drugs and cell death in cancer stem cells (CSCs)," J. Transl. Sci., vol. 6, no. 3, 2020, doi: 10.15761/JTS.1000341.

A. Remigante and R. Morabito, "Cellular and Molecular Mechanisms in Oxidative Stress-Related Diseases," Int. J. Mol. Sci., vol. 23, no. 14, p. 8017, Jul. 2022, doi: 10.3390/ijms23148017.

A. S. Mohd Zaffarin, S.-F. Ng, M. H. Ng, H. Hassan, and E. Alias, "Pharmacology and Pharmacokinetics of Vitamin E: Nanoformulations to Enhance Bioavailability," Int. J. Nanomedicine, vol. Volume 15, pp. 9961–9974, Dec. 2020, doi: 10.2147/IJN.S276355.

A. Shibata et al., "Tocotrienol Inhibits Secretion of Angiogenic Factors from Human Colorectal Adenocarcinoma Cells by Suppressing Hypoxia-Inducible Factor-1α," J. Nutr., vol. 138, no. 11, pp. 2136–2142, Nov. 2008, doi: 10.3945/jn.108.093237.

B. B. Aggarwal, C. Sundaram, S. Prasad, and R. Kannappan, "Tocotrienols, the vitamin E of the 21st century: Its potential against cancer and other chronic diseases," Biochem. Pharmacol., vol. 80, no. 11, pp. 1613–1631, Dec. 2010, doi: 10.1016/j.bcp.2010.07.043.

B. Köberle et al., "Strong apoptotic response of testis tumor cells following cisplatin treatment," Int. Urol. Nephrol., vol. 56, no. 3, pp. 1007–1017, Oct. 2023, doi: 10.1007/s11255-023-03825-5.

B. L. Sailo et al., "Therapeutic potential of tocotrienols as chemosensitizers in cancer therapy," Phyther. Res., vol. 39, no. 4, pp. 1694–1720, Apr. 2025, doi: 10.1002/ptr.8131.

B. Unal and F. Saatcioglu, "Targeting the unfolded protein response for cancer therapy: mitigating tumor adaptation and immune suppression," Biomark. Res., vol. 13, no. 1, p. 156, Dec. 2025, doi: 10.1186/s40364-025-00813-y.

C. Constantinou, C. Charalambous, D. Kanakis, O. Kolokotroni, and A. I. Constantinou, "Update on the Anti-Cancer Potency of Tocotrienols and α-Tocopheryl Polyethylene Glycol 1000 Succinate on Leukemic Cell Lines," Nutr. Cancer, vol. 73, no. 8, pp. 1302–1308, Sep. 2021, doi: 10.1080/01635581.2020.1797128.

C. K. Sen, S. Khanna, and S. Roy, "Tocotrienols: Vitamin E beyond tocopherols," Life Sci., vol. 78, no. 18, pp. 2088–2098, Mar. 2006, doi: 10.1016/j.lfs.2005.12.001.

C. Sato, S. Kaneko, A. Sato, N. Virgona, K. Namiki, and T. Yano, "Combination Effect of δ-Tocotrienol and γ-Tocopherol on Prostate Cancer Cell Growth," J. Nutr. Sci. Vitaminol. (Tokyo)., vol. 63, no. 5, pp. 349–354, 2017, doi: 10.3177/jnsv.63.349.

C. Scheau et al., "The Role of Matrix Metalloproteinases in the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma," Anal. Cell. Pathol., vol. 2019, pp. 1–10, Nov. 2019, doi: 10.1155/2019/9423907.

D. P. Anastasiadou, A. Quesnel, C. L. Duran, P. S. Filippou, and G. S. Karagiannis, "An emerging paradigm of CXCL12 involvement in the metastatic cascade," Cytokine Growth Factor Rev., vol. 75, pp. 12–30, Feb. 2024, doi: 10.1016/j.cytogfr.2023.10.003.

D. Patacsil et al., "Gamma-tocotrienol induced apoptosis is associated with unfolded protein response in human breast cancer cells," J. Nutr. Biochem., vol. 23, no. 1, pp. 93–100, Jan. 2012, doi: 10.1016/j.jnutbio.2010.11.012.

E. Curiel-Gomez, D. P. Romero-Rodriguez, M. Rodriguez-Dorantes, V. Maldonado, and J. Melendez-Zajgla, "Pancreatic Cancer Stem Cells Co-Expressing SOX2, OCT4, and TERThigh Represent an Aggressive Subpopulation," Cells, vol. 15, no. 2, p. 129, Jan. 2026, doi: 10.3390/cells15020129.

E. Meacci, A. Chirco, and M. Garcia-Gil, "Potential Vitamin E Signaling Mediators in Skeletal Muscle," Antioxidants, vol. 13, no. 11, p. 1383, Nov. 2024, doi: 10.3390/antiox13111383.

E. Pierpaoli, V. Viola, F. Pilolli, M. Piroddi, F. Galli, and M. Provinciali, "γ- and δ-tocotrienols exert a more potent anticancer effect than α-tocopheryl succinate on breast cancer cell lines irrespective of HER-2/neu expression," Life Sci., vol. 86, no. 17–18, pp. 668–675, Apr. 2010, doi: 10.1016/j.lfs.2010.02.018.

E. Ranzato and S. Martinotti, "The Interplay Between Ca2+ Homeostasis, Endoplasmic Reticulum Stress, and the Unfolded Protein Response in Human Diseases," Cells, vol. 15, no. 4, p. 352, Feb. 2026, doi: 10.3390/cells15040352.

F. D. R. Al-Baiaty, A. Ismail, Z. Abdul Latiff, K. N. Muhammad Nawawi, R. A. Raja Ali, and N. M. Mokhtar, "Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents," Front. Pediatr., vol. 9, Jul. 2021, doi: 10.3389/fped.2021.667247.

F. Fontana et al., "δ-Tocotrienol induces apoptosis, involving endoplasmic reticulum stress and autophagy, and paraptosis in prostate cancer cells," Cell Prolif., vol. 52, no. 3, May 2019, doi: 10.1111/cpr.12576.

F. Fontana, M. Marzagalli, M. Raimondi, V. Zuco, N. Zaffaroni, and P. Limonta, "δ-Tocotrienol sensitizes and re-sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPK-mediated apoptosis," Cell Prolif., vol. 54, no. 11, Nov. 2021, doi: 10.1111/cpr.13111.

F. Iannelli et al., "Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition," J. Exp. Clin. Cancer Res., vol. 39, no. 1, p. 213, Dec. 2020, doi: 10.1186/s13046-020-01723-7.

F. Khallouki et al., "An Update on Tamoxifen and the Chemo-Preventive Potential of Vitamin E in Breast Cancer Management," J. Pers. Med., vol. 13, no. 5, p. 754, Apr. 2023, doi: 10.3390/jpm13050754.

G. Liang et al., "Ameliorative effect of α-tocopherol and tocotrienol-rich palm oil extract on menopause-associated mood disorder in ovariectomized mice," Biochem. Biophys. Res. Commun., vol. 734, p. 150443, 2024, doi: https://doi.org/10.1016/j.bbrc.2024.150443.

G. P. Nagaraju, Ed., Phytochemicals Targeting Tumor Microenvironment in Gastrointestinal Cancers. Cham: Springer International Publishing, 2020. doi: 10.1007/978-3-030-48405-7.

H. M. L. Lubis, E. Purwoningsih, A. A. Nasution, and Q. M. Salim, "Mechanism of Action of Tumorigenesis of Anticancer Molecules of Palm Oil Tocotrienols (Elaeis Guieensis Jacq.): A Systematic Review," Eduvest - J. Univers. Stud., vol. 2, no. 2, pp. 431–440, Feb. 2022, doi: 10.59188/eduvest.v2i2.379.

H. Nsairat et al., "Lipid nanostructures for targeting brain cancer," Heliyon, vol. 7, no. 9, p. e07994, Sep. 2021, doi: 10.1016/j.heliyon.2021.e07994.

H. Sabit et al., "The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities," Cancer Lett., vol. 628, p. 217865, Sep. 2025, doi: 10.1016/j.canlet.2025.217865.

H. Wang, W. Yan, Y. Sun, and C. S. Yang, "δ-Tocotrienol is the Most Potent Vitamin E Form in Inhibiting Prostate Cancer Cell Growth and Inhibits Prostate Carcinogenesis in Ptenp−/− Mice," Cancer Prev. Res., vol. 15, no. 4, pp. 233–245, Apr. 2022, doi: 10.1158/1940-6207.CAPR-21-0508.

H. Yang et al., "Tocotrienols exhibit superior ferroptosis inhibition over tocopherols," Sci. Rep., vol. 16, no. 1, p. 4497, Jan. 2026, doi: 10.1038/s41598-025-34673-1.

H.-R. Park, R. Sun, R. A. Panganiban, D. C. Christiani, and Q. Lu, "MicroRNA-124 Reduces Arsenic-induced Endoplasmic Reticulum Stress and Neurotoxicity and is Linked with Neurodevelopment in Children," Sci. Rep., vol. 10, no. 1, p. 5934, Apr. 2020, doi: 10.1038/s41598-020-62594-8.

J. Mall, N. Naseem, M. F. Haider, M. A. Rahman, S. Khan, and S. N. Siddiqui, "Nanostructured lipid carriers as a drug delivery system: A comprehensive review with therapeutic applications," Intell. Pharm., 2024, doi: https://doi.org/10.1016/j.ipha.2024.09.005.

J. Zhou, K.-T. Shum, J. Burnett, and J. Rossi, "Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges," Pharmaceuticals, vol. 6, no. 1, pp. 85–107, Jan. 2013, doi: 10.3390/ph6010085.

K. C. Park, M. Dharmasivam, and D. R. Richardson, "The Role of Extracellular Proteases in Tumor Progression and the Development of Innovative Metal Ion Chelators That Inhibit Their Activity," Int. J. Mol. Sci., vol. 21, no. 18, p. 6805, Sep. 2020, doi: 10.3390/ijms21186805.

K. Chakraborty et al., "Tocotrienols inhibit PI3/Akt and ERK pathways to induce growth arrest in pancreatic cancer cell lines by downregulation of Her-2/ErbB2 receptors," Cancer Res., vol. 71, no. 8_Supplement, pp. 4490–4490, Apr. 2011, doi: 10.1158/1538-7445.AM2011-4490.

K. Husain, B. A. Centeno, D. Coppola, J. Trevino, S. M. Sebti, and M. P. Malafa, "δ-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis," Oncotarget, vol. 8, no. 19, pp. 31554–31567, May 2017, doi: 10.18632/oncotarget.15767.

K. Nesaretnam, P. Meganathan, S. D. Veerasenan, and K. R. Selvaduray, "Tocotrienols and breast cancer: the evidence to date," Genes Nutr., vol. 7, no. 1, pp. 3–9, Jan. 2012, doi: 10.1007/s12263-011-0224-z.

K. R. Selvaduray, A. K. Radhakrishnan, M. K. Kutty, and K. Nesaretnam, "Palm tocotrienols decrease levels of pro-angiogenic markers in human umbilical vein endothelial cells (HUVEC) and murine mammary cancer cells," Genes Nutr., vol. 7, no. 1, pp. 53–61, Jan. 2012, doi: 10.1007/s12263-011-0223-0.

K. Ramachandran, E. Gordian, and R. Singal, "5-Azacytidine Reverses Drug Resistance in Bladder Cancer Cells," Anticancer Res., vol. 31, pp. 3757–3766, 2011, [Online]. Available: https://ar.iiarjournals.org/content/anticanres/31/11/3757.full.pdf

K. S. Siveen et al., "γ-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model," Oncotarget, vol. 5, no. 7, pp. 1897–1911, Apr. 2014, doi: 10.18632/oncotarget.1876.

K. Szewczyk, A. Chojnacka, and M. Górnicka, "Tocopherols and Tocotrienols—Bioactive Dietary Compounds; What Is Certain, What Is Doubt?," Int. J. Mol. Sci., vol. 22, no. 12, p. 6222, Jun. 2021, doi: 10.3390/ijms22126222.

K.-L. Pang et al., "Transcriptomic Analysis of the Anticancer Effects of Annatto Tocotrienol, Delta-Tocotrienol and Gamma-Tocotrienol on Chondrosarcoma Cells," Nutrients, vol. 14, no. 20, p. 4277, Oct. 2022, doi: 10.3390/nu14204277.

K.-L. Pang, C.-W. Mai, and K.-Y. Chin, "Molecular Mechanism of Tocotrienol-Mediated Anticancer Properties: A Systematic Review of the Involvement of Endoplasmic Reticulum Stress and Unfolded Protein Response," Nutrients, vol. 15, no. 8, p. 1854, Apr. 2023, doi: 10.3390/nu15081854.

L. De Silva, L. H. Chuah, P. Meganathan, and J. Fu, "Tocotrienol and cancer metastasis," BioFactors, vol. 42, no. 2, pp. 149–162, Mar. 2016, doi: 10.1002/biof.1259.

L. Judijanto, "Investigations of palm oil components: a review of effects on immune checkpoint pathways and therapy," Open Access J. Sci., vol. 9, no. Special Issue 2026, pp. 31–39, 2026, [Online]. Available: https://medcraveonline.com/OAJS/OAJS-09-00285.pdf

L. Judijanto, "Translational Insights: A Review on Palm Oil Impacts on Immunotherapy Outcomes," Biomed. J. Sci. Tech. Res., vol. 64, no. 5, pp. 56858–56868, 2026, doi: 10.26717/BJSTR.2026.64.010093.

L. Papa and D. Germain, "Estrogen receptor mediates a distinct mitochondrial unfolded protein response," J. Cell Sci., vol. 124, no. 9, pp. 1396–1402, May 2011, doi: 10.1242/jcs.078220.

L. T. H. Phi et al., "Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment," Stem Cells Int., vol. 2018, pp. 1–16, 2018, doi: 10.1155/2018/5416923.

L. Xie and J. Yan, "γ-tocotrienol regulates gastric cancer by targeting notch signaling pathway," Hereditas, vol. 160, no. 1, p. 15, Apr. 2023, doi: 10.1186/s41065-023-00277-w.

L. Zhou, Z. Zhang, Z. Huang, E. Nice, B. Zou, and C. Huang, "Revisiting cancer hallmarks: insights from the interplay between oxidative stress and non-coding RNAs," Mol. Biomed., vol. 1, no. 1, p. 4, Dec. 2020, doi: 10.1186/s43556-020-00004-1.

L.-C. Chang, S.-K. Chiang, S.-E. Chen, and M.-C. Hung, "Exploring paraptosis as a therapeutic approach in cancer treatment," J. Biomed. Sci., vol. 31, no. 1, p. 101, Nov. 2024, doi: 10.1186/s12929-024-01089-4.

M. Montagnani Marelli et al., "Vitamin E δ-tocotrienol triggers endoplasmic reticulum stress-mediated apoptosis in human melanoma cells," Sci. Rep., vol. 6, no. 1, p. 30502, Jul. 2016, doi: 10.1038/srep30502.

M. Montagnani Marelli, C. Macchi, M. Ruscica, P. Sartori, and R. M. Moretti, "Anticancer Activity of Delta-Tocotrienol in Human Hepatocarcinoma: Involvement of Autophagy Induction," Cancers (Basel)., vol. 16, no. 15, p. 2654, Jul. 2024, doi: 10.3390/cancers16152654.

M. Montagnani Marelli, M. Marzagalli, F. Fontana, M. Raimondi, R. M. Moretti, and P. Limonta, "Anticancer properties of tocotrienols: A review of cellular mechanisms and molecular targets," J. Cell. Physiol., vol. 234, no. 2, pp. 1147–1164, Feb. 2019, doi: 10.1002/jcp.27075.

M. Stompor-Gorący, A. Włoch, P. Sengupta, A. Nasulewicz-Goldeman, and J. Wietrzyk, "Synergistic Proliferation Effects of Xanthohumol and Niflumic Acid on Merkel and Glioblastoma Cancer Cells: Role of Cell Membrane Interactions," Int. J. Mol. Sci., vol. 25, no. 20, p. 11015, Oct. 2024, doi: 10.3390/ijms252011015.

M. Yeduvaka et al., "From shield to spear: Charge-reversible nanocarriers in overcoming cancer therapy barriers," Beilstein J. Nanotechnol., vol. 17, pp. 159–175, Jan. 2026, doi: 10.3762/bjnano.17.10.

M. Younes, G. Loubnane, C. Sleiman, and S. Rizk, "Tocotrienol isoforms: The molecular mechanisms underlying their effects in cancer therapy and their implementation in clinical trials," J. Integr. Med., vol. 22, no. 1, pp. 1–11, 2024, doi: https://doi.org/10.1016/j.joim.2024.01.002.

N. A. A. Nasir, M. Z. Sadikan, and R. Agarwal, "Modulation of NFkB signalling pathway by tocotrienol: A systematic review," Asia Pac. J. Clin. Nutr., vol. 30, no. 3, pp. 537–555, 2021, doi: 10.3316/informit.165306053439068.

N. A. N. Amir Razak et al., "Effectiveness of Tocotrienol-Rich Fraction in Older Adults: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial," JMIR Res. Protoc., vol. 14, p. e73039, Sep. 2025, doi: 10.2196/73039.

N. F. Sianipar, Z. Muflikhati, D. Mangindaan, and K. Assidqi, "Anticancer Potential of Tocopherols-Containing Plants and Semi-Synthetic Tocopherols," Plants, vol. 13, no. 21, p. 2994, Oct. 2024, doi: 10.3390/plants13212994.

N. Liu et al., "Expression of matrix metalloproteinase-9, cyclooxygenase-2 and vascular endothelial growth factor are increased in gastrointestinal stromal tumors.," Int. J. Clin. Exp. Med., vol. 8, no. 4, pp. 6495–501, 2015, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/26131278

N. R. Morgan, S. Bhuvanendran, P. Krishnappa, and A. K. Radhakrishnan, "Daily Supplementation of High Doses of Tocotrienol-Rich Fraction From Palm Oil Produced No Toxic Effects in Healthy Mice," J. Toxicol., vol. 2025, no. 1, Jan. 2025, doi: 10.1155/jt/9464952.

N. S. Sulaiman et al., "Balancing functional and health benefits of food products formulated with palm oil as oil sources," Heliyon, vol. 8, no. 10, p. e11041, Oct. 2022, doi: 10.1016/j.heliyon.2022.e11041.

N. V Fernandes, P. K. Guntipalli, and H. Mo, "d-δ-Tocotrienol-mediated cell cycle arrest and apoptosis in human melanoma cells.," Anticancer Res., vol. 30, no. 12, pp. 4937–44, Dec. 2010, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/21187473

N.-V. Mohamad, "Strategies to Enhance the Solubility and Bioavailability of Tocotrienols Using Self-Emulsifying Drug Delivery System," Pharmaceuticals, vol. 16, no. 10, p. 1403, Oct. 2023, doi: 10.3390/ph16101403.

P. Ghasemiyeh and S. Mohammadi-Samani, "Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages," Res. Pharm. Sci., vol. 13, no. 4, p. 288, 2018, doi: 10.4103/1735-5362.235156.

P. Limonta, R. M. Moretti, M. Marzagalli, F. Fontana, M. Raimondi, and M. Montagnani Marelli, "Role of Endoplasmic Reticulum Stress in the Anticancer Activity of Natural Compounds," Int. J. Mol. Sci., vol. 20, no. 4, p. 961, Feb. 2019, doi: 10.3390/ijms20040961.

P. Meganathan et al., "A new formulation of Gamma Delta Tocotrienol has superior bioavailability compared to existing Tocotrienol-Rich Fraction in healthy human subjects.," Sci. Rep., vol. 5, p. 13550, Sep. 2015, doi: 10.1038/srep13550.

P. N. Chang, W. N. Yap, D. T. Wing Lee, M. T. Ling, Y. C. Wong, and Y. L. Yap, "Evidence of γ -Tocotrienol as an Apoptosis-Inducing, Invasion-Suppressing, and Chemotherapy Drug-Sensitizing Agent in Human Melanoma Cells," Nutr. Cancer, vol. 61, no. 3, pp. 357–366, May 2009, doi:

P. Ramdas, A. K. Radhakrishnan, A. A. Abdu Sani, and P. S. Abdul-Rahman, "Tocotrienols Modulate Breast Cancer Secretomes and Affect Cancer-Signaling Pathways in MDA-MB-231 Cells: A Label-Free Quantitative Proteomic Analysis," Nutr. Cancer, vol. 71, no. 8, pp. 1263–1271, Nov. 2019, doi: 10.1080/01635581.2019.1607407.

P. Sarantis, E. Koustas, A. Papadimitropoulou, A. G. Papavassiliou, and M. V Karamouzis, "Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy," World J. Gastrointest. Oncol., vol. 12, no. 2, pp. 173–181, Feb. 2020, doi: 10.4251/wjgo.v12.i2.173.

P. W. Sylvester et al., "Potential role of tocotrienols in the treatment and prevention of breast cancer," BioFactors, vol. 40, no. 1, pp. 49–58, Jan. 2014, doi: 10.1002/biof.1116.

P. W. Sylvester, A. Kaddoumi, S. Nazzal, and K. A. El Sayed, "The Value of Tocotrienols in the Prevention and Treatment of Cancer," J. Am. Coll. Nutr., vol. 29, no. sup3, pp. 324S-333S, Jun. 2010, doi: 10.1080/07315724.2010.10719847.

PhytoGaia, "Evolution of Vitamin E: The superior neuroprotective power of Tocotrienols (TocoGaia®)," Nutraceutical Business Review. Accessed: Jun. 06, 2026. [Online]. Available: https://nutraceuticalbusinessreview.com/evolution-of-vitamin-e-the-superior-neuroprotective-power

Q. Jiang, "Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy," Free Radic. Biol. Med., vol. 72, pp. 76–90, Jul. 2014, doi: 10.1016/j.freeradbiomed.2014.03.035.

R. A. Razali, W. Z. W. Ngah, S. Makpol, D. Yanagisawa, T. Kato, and I. Tooyama, "Shifting Perspectives on the Role of Tocotrienol vs. Tocopherol in Brain Health: A Scoping Review," Int. J. Mol. Sci., vol. 26, no. 13, p. 6339, Jun. 2025, doi: 10.3390/ijms26136339.

R. Comitato et al., "Tocotrienols induce endoplasmic reticulum stress and apoptosis in cervical cancer cells," Genes Nutr., vol. 11, no. 1, 2016, doi: 10.1186/s12263-016-0543-1.

R. Comitato, R. Ambra, and F. Virgili, "Tocotrienols: A Family of Molecules with Specific Biological Activities," Antioxidants, vol. 6, no. 4, p. 93, Nov. 2017, doi: 10.3390/antiox6040093.

R. K. Yadav, S.-W. Chae, H.-R. Kim, and H. J. Chae, "Endoplasmic Reticulum Stress and Cancer," J. Cancer Prev., vol. 19, no. 2, pp. 75–88, Jun. 2014, doi: 10.15430/JCP.2014.19.2.75.

R. Kannappan, S. C. Gupta, J. H. Kim, and B. B. Aggarwal, "Tocotrienols fight cancer by targeting multiple cell signaling pathways," Genes Nutr., vol. 7, no. 1, pp. 43–52, Jan. 2012, doi: 10.1007/s12263-011-0220-3.

R. Loganathan, K. R. Selvaduray, K. Nesaretnam, and A. K. Radhakrishnan, "Tocotrienols promote apoptosis in human breast cancer cells by inducing poly(ADP-ribose) polymerase cleavage and inhibiting nuclear factor kappa-B activity," Cell Prolif., vol. 46, no. 2, pp. 203–213, 2013, doi: 10.1111/cpr.12014.

R. Ranasinghe, M. Mathai, and A. Zulli, "Revisiting the therapeutic potential of tocotrienol," BioFactors, vol. 48, no. 4, pp. 813–856, Jul. 2022, doi: 10.1002/biof.1873.

R. S. Y. Wong, A. K. Radhakrishnan, T. A. T. Ibrahim, and S.-K. Cheong, "Delta- and Gamma-Tocotrienols Induce Classical Ultrastructural Apoptotic Changes in Human T Lymphoblastic Leukemic Cells," Microsc. Microanal., vol. 18, no. 3, pp. 462–469, Jun. 2012, doi: 10.1017/S1431927612000177.

S. Dangi-Garimella, S. B. Krantz, M. A. Shields, P. J. Grippo, and H. G. Munshi, "Epithelial-mesenchymal transition and pancreatic cancer progression," in Pancreatic Cancer and Tumor Microenvironment, P. J. Grippo and H. G. Munshi, Eds., Trivandrum, 2012, ch. 5. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK98932/

S. Jacob, R. Rao, B. Gorain, S. H. S. Boddu, and A. B. Nair, "Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Anticancer Phytochemical Delivery: Advances, Challenges, and Future Prospects," Pharmaceutics, vol. 17, no. 8, p. 1079, Aug. 2025, doi: 10.3390/pharmaceutics17081079.

S. K. Park, B. G. Sanders, and K. Kline, "Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling," Breast Cancer Res. Treat., vol. 124, no. 2, pp. 361–375, Nov. 2010, doi: 10.1007/s10549-010-0786-2.

S. Khanna et al., "Neuroprotective Properties of the Natural Vitamin E α-Tocotrienol," Stroke, vol. 36, no. 10, Oct. 2005, doi: 10.1161/01.STR.0000181082.70763.22.

S. M. Mohamedahmed, M. N. A. Kamarudin, P. Ramdas, A. Q. Khalid, U. Sundralingam, and A. K. Radhakrishnan, "Anticancer activities of tocotrienols: A Systematic Scoping Review," F1000Research, vol. 12, p. 402, Apr. 2023, doi: 10.12688/f1000research.132031.1.

S. Makpol, A. Z. Abidin, K. Sairin, M. Mazlan, G. M. Top, and W. Z. W. Ngah, "γ-Tocotrienol Prevents Oxidative Stress-Induced Telomere Shortening in Human Fibroblasts Derived from Different Aged Individuals," Oxid. Med. Cell. Longev., vol. 3, no. 1, pp. 35–43, Jan. 2010, doi: 10.4161/oxim.3.1.9940.

S. P. N. Bukke et al., "Solid lipid nanocarriers for drug delivery: design innovations and characterization strategies—a comprehensive review," Discov. Appl. Sci., vol. 6, no. 6, p. 279, May 2024, doi: 10.1007/s42452-024-05897-z.

S. Prasad, S. C. Gupta, A. K. Tyagi, and B. B. Aggarwal, "γ-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules," Br. J. Cancer, vol. 115, no. 7, pp. 814–824, Sep. 2016, doi: 10.1038/bjc.2016.257.

S. R. Abdul Hafid, S. Chakravarthi, K. Nesaretnam, and A. K. Radhakrishnan, "Tocotrienol-Adjuvanted Dendritic Cells Inhibit Tumor Growth and Metastasis: A Murine Model of Breast Cancer," PLoS One, vol. 8, no. 9, p. e74753, Sep. 2013, doi: 10.1371/journal.pone.0074753.

S. Sowmiya, V. Suseela, and P. R. Jeyaramraja, "Phytochemical nanoliposomes: next-generation therapeutics in precision oncology," Nano Express, vol. 6, no. 4, p. 042002, Dec. 2025, doi: 10.1088/2632-959X/ae2041.

S. U. Luk et al., "Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population," Int. J. Cancer, vol. 128, no. 9, pp. 2182–2191, May 2011, doi: 10.1002/ijc.25546.

S. V. Dharanguttikar, B. Varne, R. B. Basugade, S. S. Mali, S. A. Mujawar, and K. D. Patil, "Lipid-Based Nanocarriers (SLNs, NLCs, Liposomes): Design, Optimization, and Therapeutic Applications," Int. J. Drug Deliv. Technol., vol. 16, no. 24s, May 2026, doi: 10.25258/ijddt.16.24s.31.

S.-W. Lim, H.-S. Loh, K.-N. Ting, T. D. Bradshaw, and N. A. Zeenathul, "Cytotoxicity and apoptotic activities of alpha-, gamma- and delta-tocotrienol isomers on human cancer cells," BMC Complement. Altern. Med., vol. 14, no. 1, p. 469, Dec. 2014, doi: 10.1186/1472-6882-14-469.

S.-Y. Tham, H.-S. Loh, C.-W. Mai, and J.-Y. Fu, "Tocotrienols Modulate a Life or Death Decision in Cancers," Int. J. Mol. Sci., vol. 20, no. 2, p. 372, Jan. 2019, doi: 10.3390/ijms20020372.

T. Eitsuka, N. Tatewaki, H. Nishida, K. Nakagawa, and T. Miyazawa, "Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review," Int. J. Mol. Sci., vol. 17, no. 10, p. 1605, Sep. 2016, doi: 10.3390/ijms17101605.

V. Aggarwal et al., "Molecular Mechanisms of Action of Tocotrienols in Cancer: Recent Trends and Advancements," Int. J. Mol. Sci., vol. 20, no. 3, p. 656, Feb. 2019, doi: 10.3390/ijms20030656.

V. Jentzsch, J. Davis, and M. Djamgoz, "Pancreatic Cancer (PDAC): Introduction of Evidence-Based Complementary Measures into Integrative Clinical Management," Cancers (Basel)., vol. 12, no. 11, p. 3096, Oct. 2020, doi: 10.3390/cancers12113096.

V. Viola et al., "Why tocotrienols work better: insights into the in vitro anti-cancer mechanism of vitamin E," Genes Nutr., vol. 7, no. 1, pp. 29–41, Jan. 2012, doi: 10.1007/s12263-011-0219-9.

W. Xu, Y. Mi, P. He, S. He, and L. Niu, "γ-Tocotrienol Inhibits Proliferation and Induces Apoptosis via the Mitochondrial Pathway in Human Cervical Cancer HeLa Cells," Molecules, vol. 22, no. 8, p. 1299, Aug. 2017, doi: 10.3390/molecules22081299.

X. Kang et al., "A Sono-Responsive Nanoplatform Integrating STING Activation and CXCR4 Blockade for Synergistic Immunotherapy of Glioblastoma," Adv. Mater., vol. 38, no. 7, Feb. 2026, doi: 10.1002/adma.202512104.

X. Zhang et al., "Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells," BMC Cancer, vol. 15, no. 1, p. 866, Dec. 2015, doi: 10.1186/s12885-015-1851-3.

Y. T. Murindangabo et al., "Quantitative Approaches in Assessing Soil Organic Matter Dynamics for Sustainable Management," Agronomy, vol. 13, no. 7, p. 1776, Jun. 2023, doi: 10.3390/agronomy13071776.

Y.-G. Li et al., "Role of paraptosis in cancer: Molecular mechanisms and therapeutic potentials," Exp. Cell Res., vol. 460, no. 1, p. 115050, Jul. 2026, doi: 10.1016/j.yexcr.2026.115050.

Y.-H. Lin et al., "Inhibition of lncRNA RPPH1 activity decreases tumor proliferation and metastasis through down-regulation of inflammation-related oncogenes.," Am. J. Transl. Res., vol. 15, no. 12, pp. 6701–6717, 2023, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/38186977

Z. Fu, B. Zheng, J. Zhang, J. Ruan, and D. Zheng, "Nanoscale delivery systems for hepatocellular carcinoma: Functionalization, delivery strategies, and clinical challenges," Mater. Today Bio, vol. 38, p. 103227, Jun. 2026, doi: 10.1016/j.mtbio.2026.103227.

Z. Odak et al., "Deciphering the Interplay: Thieno[2,3-b]pyridine's Impact on Glycosphingolipid Expression, Cytotoxicity, Apoptosis, and Metabolomics in Ovarian Tumor Cell Lines," Int. J. Mol. Sci., vol. 25, no. 13, p. 6954, Jun. 2024, doi: 10.3390/ijms25136954.

Z. Sun, X. Ma, C. Zhao, L. Fan, S. Yin, and H. Hu, "Delta-tocotrienol disrupts PD-L1 glycosylation and reverses PD-L1-mediated immune suppression," Biomed. Pharmacother., vol. 170, p. 116078, Jan. 2024, doi: 10.1016/j.biopha.2023.116078.

Z. Villines, "What you need to know about tocotrienols," Medical News Today. Accessed: Jun. 06, 2026. [Online]. Available: https://www.medicalnewstoday.com/articles/319689

Z. Xie et al., "Randomized controlled trial for time-restricted eating in healthy volunteers without obesity," Nat. Commun., vol. 13, no. 1, p. 1003, Feb. 2022, doi: 10.1038/s41467-022-28662-5.